MALVERN, Pa., Jan. 29 /PRNewswire/ -- Today Neuron Therapeutics, Inc., a developer of novel treatments for neurologic disorders, announced the initiation of a Phase I clinical safety trial in patients suffering from severe ischemic stroke. Neuron Therapeutics received FDA approval in late 2000 to begin clinical trials of its lead drug candidate, Revoxyn*, an oxygenated fluorocarbon nutrient emulsion ("OFNE"). Revoxyn* has been the subject of extensive pre-clinical trials that have demonstrated its ability to limit the brain damage that typically results from stroke. Multiple pre-clinical studies have shown that treatment with Revoxyn* several hours after initiation of a severe stroke acts to reduce the amount of swelling and damage to brain tissue that is caused by the sudden interruption in blood flow. The first patient was recently treated with this investigational therapy at Thomas Jefferson University Hospital. "The use of Revoxyn* in this first patient is the culmination of intensive research and development, " said Bruce Shook, President and CEO of Neuron Therapeutics, Inc. "This is a very promising beginning of the clinical phase of our development program for this unique drug product. It forms the basis of our plan to utilize our direct delivery platform for the treatment of central nervous system disorders." Philadelphia's Thomas Jefferson University Hospital is playing a key role in the development of this new drug. Neuron Therapeutics' novel drug and its delivery system are the outgrowth of research at Thomas Jefferson University, whose hospital is the first site testing this technology. Both the clinicians and patients involved in this initial clinical trial come from the Philadelphia metropolitan area. Stroke affects the lives of more than 750,000 Americans each year and is the third leading cause of death in this country. Over 80 percent of strokes are ischemic, meaning they involve interruption of blood flow to the brain. To date, the only FDA-approved drug treatment for ischemic stroke is one that targets the actual clot inside a blocked blood vessel. This treatment is suitable for only a very small number of patients, and for the remaining patients suffering the most severe strokes, there is no approved treatment option. Neuron Therapeutics is dedicated to developing a new therapy that gives patients an alternative treatment, especially for the most severe cases. This novel therapy bypasses the blocked blood vessels and delivers oxygen and nutrients directly to the injured brain tissue. "Stroke treatment represents an enormous unmet medical need. The approach Neuron Therapeutics is taking is remarkably different from anything that has been tried before in that it involves direct delivery of oxygen and nutrients to oxygen-starved brain tissue," explained Dr. Rodney Bell, principal investigator on the project and Director of the Jefferson Stroke Center and Division of Cerebrovascular Disease and Neurologic Critical Care at Thomas Jefferson University Hospital. Neuron Therapeutics, Inc. is based in Malvern, PA and is a privately held company engaged in the development of proprietary new drugs and medical devices for the treatment of disorders of the central nervous system. Revoxyn* is Neuron's platform technology, and the company is currently focused on applying its novel drug and delivery system to the treatment of stroke. For further information contact Bruce Shook, CEO, at 610-578-9120. Additional information about Neuron Therapeutics is available on our web site at http://www.neurontherapeutics.com . Information about the clinical trial is available at the Thomas Jefferson University Hospital web site at http://www.jeffersonhospital.org/stroketrial . Revoxyn* is a trademark of Neuron Therapeutics, Inc. Except for the historical information contained herein, this statement may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. The Company wishes to caution you that such statements are just predictions. Actual events or results may differ materially.
SOURCE Neuron Therapeutics, Inc.